Chemotherapy-induced pulmonary complications in cancer: Significance of clinicoradiological correlation

Abstract

Chemotherapy while revolutionizing cancer management by improving survival and quality of life; is also associated with several adverse effects. Lung is the most common organ affected in chemotherapy-related complications, due to either drug toxicity or more commonly due to infections caused by immunosuppression and less commonly due to immune-mediated injury. Radiology, when used in combination with clinical and lab data, can help reach the specific diagnosis or narrow down the differentials. The common radiological patterns of drug toxicity include pulmonary interstitial and airway infiltrates, diffuse alveolar damage, nonspecific interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pulmonary hemorrhage, edema and hypertension. Cancer patients are immunosuppressed due to the underlying malignancy itself or due to therapy and are prone to a gamut of opportunistic infections including viral, bacterial, fungal and mycobacterial pathogens. Immune reconstitution inflammatory syndrome (IRIS), a well-known complication in HIV, is now being increasingly recognized in non-HIV patients with immunosuppression. Engraftment syndrome is specifically seen following hematopoietic stem cell transplant during neutrophil recovery phase. Pulmonary involvement is frequent, causing a radiological picture of noncardiogenic pulmonary edema. Thus, radiology in combination with clinical background and lab parameters helps in detecting and differentiating various causes of pulmonary complications. This approach can help alter potentially toxic treatment and initiate early treatment depending on the diagnosis.

Keywords

Chemotherapy - engraftment syndrome - pulmonary drug toxicity - pulmonary infections

• References

• 1 Martin L, Schilder RJ. Novel non-cytotoxic therapy in ovarian cancer: Current status and future prospects. J Natl Compr Cancer Netw 2006; 4: 955-66
• 2 Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol Off J Eur Soc Med Oncol 2006; 17: 372-9
• 3 Oh YW, Effmann EL, Godwin JD. Pulmonary infections in immunocompromised hosts: Importance of correlating the conventional radiologic appearance with the clinical setting. Radiology 2000; 217: 647-56
• 4 Stover DE, Kaner RJ. Pulmonary complications in cancer patients. CA Cancer J Clin 1996; 46: 303-20
• 5 Sun H-Y, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis 2009; 22: 394-402
• 6 Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321-40
• 7 Matsuno O. Drug-induced interstitial lung disease: Mechanisms and best diagnostic approaches. Respir Res 2012; 13: 39
• 8 Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004; 25: 37-45
• 9 Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O’Regan K. et al. New targeted molecular therapies for cancer: Radiological response in intrathoracic malignancies and cardiopulmonary toxicity: What the radiologist needs to know. Cancer Imaging 2014; 14: 26
• 10 Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res 2015; 4: 36-54
• 11 Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006; 33: 98-105
• 12 Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001; 13: 242-8
• 13 Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: Radiologic and pathologic manifestations. RadioGraphics 2000; 20: 1245-59
• 14 Cardinale L, Asteggiano F, Moretti F, Torre F, Ulisciani S, Fava C. et al. Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. World J Radiol 2014; 6: 583-8
• 15 Du Bois R, King TE. Challenges in pulmonary fibrosis 5: The NSIP/UIP debate. Thora× 2007; 62: 1008-12
• 16 Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Can Respir J Can Thorac Soc 2013; 20: 153-5
• 17 Debnath J, Singh H, George R, Satija L, Chawla N, Sarma Y. et al. Reversible bleomycin toxicity. Med J Armed Forces India 2010; 66: 290-1
• 18 Ikeda S, Sekine A, Kato T, Yoshida M, Ogata R, Baba T. et al. Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: An autopsy case. Jpn J Clin Oncol 2014; 44: 497-500
• 19 Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: Etiologies, pathophysiology, and management. Kidney Int 2017; 92: 37-46
• 20 Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP. et al. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 1993; 11: 399-401
• 21 Teutonico A, Chimienti D, Antonelli M, Bruno A, Libutti P, Lisi P. et al. The systemic capillary leak syndrome: A scarcely known nephrological entity. J Nephrol 2012; 25: 262-5
• 22 Tazelaar HD, Linz LJ, Colby TV, Myers JL, Limper AH. Acute eosinophilic pneumonia: Histopathologic findings in nine patients. Am J Respir Crit Care Med 1997; 155: 296-302
• 23 From E. Methotrexate pneumonitis in a psoriatic. Br J Dermatol 1975; 93: 107-10
• 24 Jeong YJ, Kim K-I, Seo IJ, Lee CH, Lee KN, Kim KN. et al. Eosinophilic lung diseases: A clinical, radiologic, and pathologic overview. Radiographics 2007; 27: 617-37
• 25 Niksarlıoğlu EY, Özkan GZ, Bakan ND, Yurt S, Kılıç L, Çamsarı G. Cryptogenic organizing pneumonia: Clinical and radiological features, treatment outcomes of 17 patients, and review of the literature. Turk J Med Sci 2016; 46: 1712-8
• 26 Nazer L, Alnajjar T, Salah S, Khzouz J, Alfaqeer N, Qandeel M. Fatal case of cryptogenic organizing pneumonia associated with everolimus. Ann Saudi Med 2014; 34: 437-9
• 27 Glazer CS. Chronic hypersensitivity pneumonitis: Important considerations in the work-up of this fibrotic lung disease. Curr Opin Pulm Med 2015; 21: 171-7
• 28 Sousa D, Justo I, Domínguez A, Manzur A, Izquierdo C, Ruiz L. et al. Community-acquired pneumonia in immunocompromised older patients: Incidence, causative organisms and outcome. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2013; 19: 187-92
• 29 Diederich S. Chest CT for suspected pulmonary complications of oncologic therapies: How I review and report. Cancer Imaging Off Publ Int Cancer Imaging Soc 2016; 16: 7
• 30 Lee YR, Choi YW, Lee KJ, Jeon SC, Park CK, Heo JN. CT halo sign: The spectrum of pulmonary diseases. Br. J. Radiol 2005; 78: 862-5
• 31 Marom EM, Kontoyiannis DP. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients. Curr Opin Infect Dis 2011; 24: 309-14
• 32 Mu X-D, Jia P, Gao L, Su L, Zhang C, Wang R-G. et al. Relationship between radiological stages and prognoses of pneumocystis pneumonia in non-AIDS immunocompromised patients. Chin Med J (Engl) 2016; 129: 2020-5
• 33 Sharma SK, Soneja M. HIV and immune reconstitution inflammatory syndrome (IRIS). Indian J Med Res 2011; 134: 866-77
• 34 Alawin IA, Karnath BM. Paradoxical immune reconstitution syndrome presenting as acute respiratory distress syndrome in a Leukemia patient during neutrophil recovery. Case Rep Hematol 2012; 2012: 670347
• 35 Rajeswaran G, Becker JL, Michailidis C, Pozniak AL, Padley SPG. The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: Appearances in 11 patients. Clin Radiol 2006; 61: 833-43
• 36 Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-8
• 37 Deeg HJ. Cytokines in graft-versus-host disease and the graft-versus-Leukemia reaction. Int J Hematol 2001; 74: 26
• 38 Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ. et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: Incidence and effects on survival. Biol Blood Marrow Transplant 2005; 11: 542-50